Prostaglandin E2 inhibits mast cell–dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor Jesper Säfholm,

Slides:

Advertisements

Similar presentations

Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy Yitzhak Katz, MD, Nelly Rajuan, MSc, Michael R. Goldberg,

Advertisements

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD

Quoting a landmark paper on the beneficial effects of probiotics

Airway fibroblasts exhibit a synthetic phenotype in severe asthma

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Factor XII–independent cleavage of high-molecular-weight kininogen by prekallikrein and inhibition by C1 inhibitor Kusumam Joseph, PhD, Baby G. Tholanikunnel,

Prostaglandin E2 suppresses CCL27 production through EP2 and EP3 receptors in human keratinocytes Naoko Kanda, MD, PhD, Hiroshi Mitsui, MD, PhD, Shinichi.

Ramipril and metoprolol intake aggravate human and murine anaphylaxis: Evidence for direct mast cell priming Maria Nassiri, MS, Magda Babina, PhD, Sabine.

Siglec-7 is an inhibitory receptor on human mast cells and basophils

Is 9 more than 2 also in allergic airway inflammation?

Cysteinyl leukotriene E4 activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D2 and epithelial cytokines Maryam Salimi,

Lung mast cells are a source of secreted phospholipases A2

Jovana Maric, MSc, Avinash Ravindran, MSc, Luca Mazzurana, MSc, Åsa K

Inhibition of FcεRI-dependent mediator release and calcium flux from human mast cells by sialic acid–binding immunoglobulin-like lectin 8 engagement

Clavulanic acid can be the component in amoxicillin-clavulanic acid responsible for immediate hypersensitivity reactions Maria José Torres, MD, PhD,

Prostaglandin E2 suppresses allergic sensitization and lung inflammation by targeting the E prostanoid 2 receptor on T cells Zbigniew Zasłona, PhD, Katsuhide.

Efren Rael, MD, FAAAAI Journal of Allergy and Clinical Immunology

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

Human lung natural killer cells are predominantly comprised of highly differentiated hypofunctional CD69−CD56dim cells Nicole Marquardt, PhD, Eliisa.

Imatinib stimulates prostaglandin E2 and attenuates cytokine release via EP4 receptor activation Thomas Bärnthaler, MD, Katharina Jandl, PhD, Heinz Sill,

Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors Donald W. MacGlashan, MD, PhD,

Donald W. MacGlashan, MD, PhD, Sarbjit S. Saini, MD

Debra J. Palmer, PhD, Thomas R. Sullivan, BMa&CompSc(Hons), Michael S

Thymic stromal lymphopoietin as a mediator of crosstalk between bronchial smooth muscles and mast cells Zoulfia Allakhverdi, PhD, Michael R. Comeau,

Prostaglandin E2 suppresses allergic sensitization and lung inflammation by targeting the E prostanoid 2 receptor on T cells Zbigniew Zasłona, PhD, Katsuhide.

Prostaglandin E2 suppresses staphylococcal enterotoxin–induced eosinophilia- associated cellular responses dominantly through an E-prostanoid 2–mediated.

Prostaglandin E2 resistance in granulocytes from patients with aspirin-exacerbated respiratory disease Tanya M. Laidlaw, MD, Anya J. Cutler, Molly S.

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Update on the role of prostaglandins in allergic lung inflammation: Separating friends from foes, harder than you might think Martin L. Moore, PhD, R.

Josée Lamoureux, PhD, Jana Stankova, PhD, Marek Rola-Pleszczynski, MD

What is an “eosinophilic phenotype” of asthma?

Lora G. Bankova, MD, Joshua A. Boyce, MD

Bitter taste receptor (TAS2R) agonists inhibit IgE-dependent mast cell activation Maria Ekoff, PhD, Jeong-Hee Choi, MD, PhD, Anna James, PhD, Barbro Dahlén,

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Autophagy: Nobel Prize 2016 and allergy and asthma research

Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells Luzheng Xue, PhD,

Leukotriene D4 and prostaglandin E2 signals synergize and potentiate vascular inflammation in a mast cell–dependent manner through cysteinyl leukotriene.

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Ian Ashmole, PhD, S. Mark Duffy, PhD, Mark L. Leyland, PhD, Valerie S

Activation of human mast cells through the platelet-activating factor receptor Naoki Kajiwara, PhD, Tomomi Sasaki, BSc, Peter Bradding, DM, Glenn Cruse,

Matthew J. Loza, PhD, Susan Foster, PhD, Stephen P

Sara Paveglio, PhD, MS, Erin Bennett, MS, Kelly L. Hawley, PhD, Adam P

Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab Donald W. MacGlashan,

Acquisition and alteration of adhesion molecules during cultured human mast cell differentiation Hiroshi Tachimoto, MD, PhD, Sherry A. Hudson, MSB, Bruce.

Asifa K. Zaidi, PhD, Sarbjit S. Saini, MD, Donald W

Levels of nitric oxide oxidation products are increased in the epithelial lining fluid of children with persistent asthma Anne M. Fitzpatrick, PhD, Lou.

Bill T. Ameredes, PhD, William J. Calhoun, MD

Prostaglandin E receptor subtype EP3 in conjunctival epithelium regulates late-phase reaction of experimental allergic conjunctivitis Mayumi Ueta, MD,

D-type prostanoid receptor enhances the signaling of chemoattractant receptor– homologous molecule expressed on TH2 cells Miriam Sedej, MSc, Ralf Schröder,

Physiologic assessment of allergic rhinitis in mice: Role of the high-affinity IgE receptor (FcɛRI) Satoko Miyahara, MD, PhD, Nobuaki Miyahara, MD, PhD,

Leukotriene D4 induces gene expression in human monocytes through cysteinyl leukotriene type I receptor Grzegorz Woszczek, MD, PhD, Li-Yuan Chen, PhD,

Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function Clare Hardman,

CCL17/thymus and activation-regulated chemokine induces calcitonin gene–related peptide in human airway epithelial cells through CCR4 Kandace Bonner,

Staphylococcus aureus enterotoxin B, protein A, and lipoteichoic acid stimulations in nasal polyps Joke Patou, MD, Philippe Gevaert, MD, PhD, Thibaut.

Acid-suppressive drug use in pregnancy and the toddler's asthma risk: A crossover, case-control study Bianca Mulder, BSc, Catharina Carolina Maria Schuiling-Veninga,

Clinical and pathologic perspectives on aspirin sensitivity and asthma

Toll-like receptor agonists differentially regulate cysteinyl-leukotriene receptor 1 expression and function in human dendritic cells Maryse Thivierge,

Endothelial E-type prostanoid 4 receptors promote barrier function and inhibit neutrophil trafficking Viktoria Konya, PhD, Andreas Üllen, PhD, Nora Kampitsch,

Effects of selective COX-2 inhibition on allergen-induced bronchoconstriction and airway inflammation in asthma Kameran Daham, MD, PhD, Anna James, PhD,

Human basophils may not undergo modulation by DC-SIGN and mannose receptor– targeting immunotherapies due to absence of receptors Mrinmoy Das, MSc, Caroline.

Steroids completely reverse albuterol-induced β2-adrenergic receptor tolerance in human small airways Philip R. Cooper, PhD, Reynold A. Panettieri, MD

Päivi M. Salo, PhD, Samuel J. Arbes, DDS, MPH, PhD, Patrick W

Asthma: The past, future, environment, and costs

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

The effects of an H3 receptor antagonist (PF ) with fexofenadine on reducing allergic rhinitis symptoms Jeffrey R. Stokes, MD, Francisco A. Romero,

The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy Jennifer M. Maloney, MD, Magnus Rudengren, BSc, Staffan.

Transforming growth factor β1 increases fibronectin deposition through integrin receptor α5β1 on human airway smooth muscle Lyn M. Moir, PhD, Janette.

Natural history of cow’s milk allergy

CCL17/thymus and activation-regulated chemokine induces calcitonin gene–related peptide in human airway epithelial cells through CCR4 Kandace Bonner,

Presentation transcript:

Prostaglandin E2 inhibits mast cell–dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor Jesper Säfholm, PhD, Martijn L. Manson, PharmD, Johan Bood, MD, Ingrid Delin, BSc, Ann-Charlotte Orre, MD, Per Bergman, MD, PhD, Mamdoh Al-Ameri, MD, Sven-Erik Dahlén, MD, PhD, Mikael Adner, PhD Journal of Allergy and Clinical Immunology Volume 136, Issue 5, Pages 1232-1239.e1 (November 2015) DOI: 10.1016/j.jaci.2015.04.002 Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Concentration-response curves of agonists in human small bronchi. A, Cumulative addition of PGE2 at baseline in the presence or absence of the selective EP4 receptor antagonist ONO-AE3-208 (1 μmol/L). B, Cumulative addition of PGE2 in the presence or absence of the selective EP2 receptor antagonist PF-04418948 (1 μmol/L) or ONO-AE3-208 (1 μmol/L) on segments precontracted with histamine (1 μmol/L). C, Cumulative addition of the long-acting β-adrenergic receptor agonist formoterol or the selective EP4 receptor agonist TCS 2510 on segments precontracted with histamine (1 μmol/L). Data on contractions in Fig 1, A, are related to maximum contraction, whereas data in Fig 1, B and C, are expressed in percentages of maximal relaxation from histamine precontraction (see the Methods section). Relaxations were studied in the presence of the selective TP receptor antagonist SQ-29,548 (1 μmol/L). Data represent means ± SEMs (n = 7-10). Journal of Allergy and Clinical Immunology 2015 136, 1232-1239.e1DOI: (10.1016/j.jaci.2015.04.002) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Contractions of human small bronchi in response to prostanoids. Concentration response relations for all examined agonists (A), followed by separate investigation of PGE2 (B), 17-phenyl trinor PGE2 (C), AL-8810 (control response in gray-shaded bars; D), PGD2 (E), and U-46619 (F) in the presence (black-shaded parts of bars) or absence (open bars) of the selective TP receptor antagonist SQ-29,548 (1 μmol/L), selective EP1 receptor ONO-8130 (1 μmol/L; light gray shading), or selective EP3 receptor antagonist ONO-AE5-599 (1 μmol/L; dark gray shading). The contraction of each segment in all experiments was calculated as a percentage in relation to maximal contraction. All experiments were performed in the presence of the selective EP4 receptor antagonist ONO-AE3-208 (1 μmol/L). Data represent means ± SEMs (n = 8). Journal of Allergy and Clinical Immunology 2015 136, 1232-1239.e1DOI: (10.1016/j.jaci.2015.04.002) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Anti-IgE exposure. A, Concentration response of anti-human IgE mAb in the presence or absence of the selective H1 receptor antagonist mepyramine (1 μmol/L), selective TP receptor antagonist SQ-29,548 (1 μmol/L), or selective 5-lipoxygenase–activating protein inhibitor MK-886 (1 μmol/L). B, Time course after anti-IgE exposure (51.8 μg/mL) pretreated with PGE2 (0.1-10 μmol/L). C, Pretreatment with PGE2 (0.1 μmol/L) during different time points (15-120 minutes). D, In the presence or absence of selective EP2 receptor antagonist PF-04418948 (1 μmol/L) or selective EP4 receptor antagonist ONO-AE3-208 (1 μmol/L), followed by PGE2 (10 μmol/L) 15 minutes before anti-IgE exposure. Fig 3, B-D, shows experiments performed in the presence of the selective TP receptor antagonist SQ-29,548 (1 μmol/L), and for the experiments shown in Fig 3, B and C, ONO-AE3-208 (1 μmol/L) was included. Contraction of each segment in all experiments was calculated as a percentage in relation to maximal tissue contraction. Data represent means ± SEMs (n = 5-9). Journal of Allergy and Clinical Immunology 2015 136, 1232-1239.e1DOI: (10.1016/j.jaci.2015.04.002) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 Measurement of released histamine (30 minutes; A) and CysLTs (60 minutes; B) in the presence or absence of PGE2 (100 nmol/L) or a combination of PGE2 and the selective EP2 receptor antagonist PF-04418948 (1 μmol/L) in relation to tissue wet weight after anti-IgE (51.8 μg/mL) exposure. Data represent means ± SEMs (n = 5). Journal of Allergy and Clinical Immunology 2015 136, 1232-1239.e1DOI: (10.1016/j.jaci.2015.04.002) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 5 Concentration-response curve of LTD4 and histamine in the presence or absence of PGE2 (10 μmol/L). All experiments were performed in the presence of the selective TP receptor antagonist SQ-29,548 (1 μmol/L) and selective EP4 receptor antagonist ONO-AE3-208 (1 μmol/L) to allow for comparison with the anti-IgE experiments in Fig 3. Data represent means ± SEMs (n = 8). Journal of Allergy and Clinical Immunology 2015 136, 1232-1239.e1DOI: (10.1016/j.jaci.2015.04.002) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions